Photo of Alexey V. Danilov, M.D., Ph.D.

Alexey V. Danilov M.D., Ph.D.

    • Associate Professor of Medicine School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine
    • Cancer Biology Graduate Program School of Medicine

Dr. Alexey Danilov is a physician with special expertise in lymphoma and chronic lymphocytic leukemia. In addition to taking care of patients with lymphoma and CLL, Dr. Danilov initiates and leads clinical trials and heads a research laboratory which investigates novel therapeutic targets in lymphoma. Importantly, in collaboration with industry, his research team translates bench discoveries into early-phase clinical trials, which are poised to improve lives of patients by developing safe and effective new treatments. Dr. Danilov is a Lymphoma Research Foundation Clinical Investigator and a Leukemia and Lymphoma Society Scholar in Clinical Research. He and his research team are recipients of numerous awards, including the Leukemia and Lymphoma Society Translational Research Program Award, American Society of Hematology Abstract Achievement Award, Gazzaniga Family Prize, Professor Albitski Prize and others. His research is consistently featured at national and international meetings.

Dr. Danilov developed new clinical trials which target the tumor-supporting niche; optimized treatment regimens for older patients with CLL; defined novel ways to target the tumor niche in lymphoma and CLL; discovered how novel class of drugs, CDK inhibitors, kill tumor cells.

Read more

Education

  • M.D., Yaroslavl State Medical Academy, Yaroslavl 1997
  • Ph.D., Yaroslavl State Medical Academy, Yaroslavl 2000
  • Residency:

    • Internal medicine, Brown University School of Medicine, 2007
  • Fellowship:

    • Hematology-oncology, Tufts Medical Center, Boston, 2010
  • Certifications:

    • American Board of Internal Medicine: internal medicine, 2007
    • American Board of Internal Medicine: medical oncology, 2010
    • American Board of Internal Medicine: hematology, 2012

Publications

  • "Functional genomic landscape of acute myeloid leukaemia." Nature  In: , Vol. 562, No. 7728, 25.10.2018, p. 526-531.
  • "Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib." Cancer  In: , Vol. 124, No. 15, 01.08.2018, p. 3192-3200.
  • "Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy." Cancer  In: , Vol. 124, No. 11, 01.06.2018, p. 2306-2315.
  • "Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples." Oncotarget  In: , Vol. 9, No. 37, 15.05.2018, p. 24576-24589.
  • "Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma." Leukemia and Lymphoma  In: , 18.04.2018, p. 1-9.
  • "Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia." Leukemia and Lymphoma  In: , 19.12.2017, p. 1-3.
  • "SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia." Haematologica  In: , Vol. 102, No. 11, 27.10.2017, p. 1890-1900.
  • "Role for ZAP-70 signaling in the differential effector functions of rituximab and obinutuzumab (GA101) in chronic lymphocytic leukemia B cells." Journal of Immunology  In: , Vol. 199, No. 4, 15.08.2017, p. 1275-1282.
  • "Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities–is there an optimal dose?" Expert Review of Hematology  In: , Vol. 10, No. 8, 03.08.2017, p. 707-718.
  • "Ibrutinib-associated bleeding : pathogenesis, management and risk reduction strategies." Journal of Thrombosis and Haemostasis  In: , Vol. 15, No. 5, 01.05.2017, p. 835-847.
  • "Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma." British Journal of Clinical Pharmacology  In: , Vol. 83, No. 4, 2017, p. 846-854.
  • "Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis." Oncotarget  In: , Vol. 8, No. 13, 2017, p. 21128-21139.
  • "Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2." Molecular Cancer Therapeutics  In: , Vol. 15, No. 11, 01.11.2016, p. 2758-2766.
  • "Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL) : a sub-analysis of SWOG S0816 Phase 2 trial." Leukemia and Lymphoma  In: , 07.07.2016, p. 1-5.
  • "Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105." Cancer Biology and Therapy  In: , 11.02.2016, p. 1-9.
  • "Cardiac non-Hodgkin's lymphoma : Clinical characteristics and trends in survival." European Journal of Haematology  In: , 2016.
  • "A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities." British Journal of Haematology  In: , 2016.
  • "Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia." British Journal of Haematology  In: , 2016.
  • "Acute inflammatory skin reaction during neutrophil recovery after antileukemic therapy." Cutis  In: , Vol. 98, No. 4, 2016, p. E13-E15.
  • "Urticarial linear IgA bullous dermatosis (LABD) as a presenting sign of chronic lymphocytic leukemia (CLL)." JAAD Case Reports  In: , Vol. 1, No. 6, 01.11.2015, p. 412-414.
  • "Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-cells." PLoS One  In: , Vol. 10, No. 11, e0143685, 01.11.2015.
  • "Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange." Journal of Clinical Apheresis  In: , Vol. 30, No. 5, 01.10.2015, p. 308-310.
  • "Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia." British Journal of Haematology  In: , Vol. 170, No. 5, 01.09.2015, p. 734-736.
  • "Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo." British Journal of Clinical Pharmacology  In: , Vol. 80, No. 3, 01.09.2015, p. 493-501.
  • "Pericardial involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma." Blood  In: , Vol. 126, No. 3, 16.07.2015, p. 424.
  • "MIR21 is differentially expressed in the lymphoid tissue and modulated by stromal signalling in chronic lymphocytic leukaemia." British Journal of Haematology  In: , Vol. 170, No. 2, 01.07.2015, p. 272-275.
  • "Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia b cells to Alkylating agents." Cell Death and Disease  In: , Vol. 6, No. 7, e1807, 01.07.2015.
  • "CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110." Cancer Research  In: , Vol. 75, No. 10, 15.05.2015, p. 2029-2038.
  • "Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells." Leukemia and Lymphoma  In: , Vol. 56, No. 5, 01.05.2015, p. 1566-1569.
  • "Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia - response to Rider et al." British Journal of Haematology  In: , 2015.

Additional information

Edit profile